Antithrombin Activity
Antithrombin is a serine proteinase inhibitor (serpin) that controls the process of coagulation. The inhibitory activity of antithrombin is controlled by its interaction with the co-factor heparin. There are two types of hereditary antithrombin deficiency states, types I and II. Type I deficiency states are characterized by both a quantitative deficiency of antithrombin (low antigen) and low activity (low function). Type II is characterized by a functional decrease in antithrombin activity with a normal antigen level. Hereditary antithrombin deficiency is autosomal dominant. Heterozygous individuals usually develop symptoms in their late thirties and show plasma activity levels of 40 - 70% of normal. In terms of patients with hereditary thrombophilic diseases (eg, Factor V Leiden and protein C and S deficiency), patients with antithrombin deficiency may have the highest risk of venous thrombosis. Patients with Type I mutations are strongly correlated with a predisposition toward venous thrombosis and pulmonary embolism. Very rarely, an individual might be homozygous (congenital AT III deficiency), where both antithrombin genes are mutated, resulting in severe thrombotic problems soon after birth and very early death. Type II mutations are usually point mutations or single amino acid changes that result in an antithrombin molecule that is synthesized and usually secreted into the plasma in normal amounts; however, the molecule is defective and dysfunctional. This dysfunction can be attributed to:
- Impaired stability, thus lowering the effective life of the active molecule
- Impaired activity of the molecule, resulting in a loss of inhibitory activity in the absence or presence of heparin and loss of affinity for heparin
Hereditary or acquired antithrombin deficiency may result in the condition of Heparin Therapy Resistance characterized by a need for larger than normal doses of heparin in order to reach a desired level of therapeutic effect. Type II deficiencies are sometimes correlated with thrombosis. Differentiation between types of deficiency can be detected, differentiated, and assessed using two antithrombin tests: antithrombin activity, which evaluates the function of a patient’s antithrombin (usually qualitative), and antithrombin antigen, which measures the quantity of antithrombin present. The antithrombin activity test is performed before the antigen test, to evaluate whether the total amount of functional antithrombin is normal. Activity will be decreased with both type 1 and type 2 antithrombin deficiencies, so this test can be used as an initial screen for both. If the antithrombin activity is low, then the antithrombin antigen test is performed to determine the quantity of antithrombin present. If a deficiency is detected, both antithrombin tests are repeated at a later date to confirm test findings. Antithrombin testing may be used to evaluate patients not responding as expected to heparin. Acquired deficiencies of antithrombin III may be due to cirrhosis of the liver, postoperative recovery, DIC, and nephrotic syndrome.
- Evaluation of hypercoagulable disorders
- Evaluation of recurrent venous thrombosis
- To evaluate response to heparin
- As an aid in diagnosis of the hereditary deficiency of antithrombin III
- As an aid in diagnosis of acquired deficiency due to severe cirrhosis, chronic liver failure, DIC, thrombolytic therapy, pulmonary embolism, nephrotic syndrome, or post-surgical state (especially liver transplant or partial hepatectomy) must be excluded
- Antithrombin III levels might also be of use in cases of suspected hepatic failure, general or orthopedic surgery, prolonged bed rest, pregnancy, postpartum or postoperative state, or oral contraceptive use
Increased:
- Acute hepatitis/cholestasis, kidney transplant
- Vitamin K deficiency
- Warfarin (coumadin) anticoagulation therapy
Note: Increased levels of antithrombin are not usually considered problematic
Decreased in:
- Congenital and acquired AT III deficiency (proteinuria, nephrotic syndrome, liver disease)
- Oral contraceptive use
- Disseminated intravascular coagulation (DIC)
- Acute venous thrombosis (consumption)
- L-asparaginase treatment
- Heparin therapy
- Estrogen therapy
- Carbohydrate-deficient glycoprotein syndromes
Definitive diagnosis of hereditary deficiency may require multiple testing of the patient and family members. There appears to be no significance to elevated antithrombin levels. Heparin therapy may result in decreased levels of antithrombin.
84–123% (enzymatic activity, qualitative)
80–130% (antigen, quantitative)
Sample Type
Plasma Citrate - (Blue Top)
Temperature
Frozen
Special Instructions
Centrifuged to produce platelet poor plasma, separated immediatly and freeze.
- Int J Biochem Cell Biol. 2004;36:386. [PMID: 14687916]
- J Thromb Haemost. 2005 Mar;3(3):459-64. [PMID: 15748234]
- Thromb Haemost. 2005;3:459. [PMID: 15748234]
- Haematologica. 2007 Aug;92(8):1107-14 [PMID: 17650440]
- Haematologica. 2006;91:695. [PMID: 16670075]